Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: David Cathcart who wrote (684)	2/17/1998 7:03:00 PM
From: the eagle	Read Replies (2) \| Respond to of 1826

assuming, a europe partner then what do they get out of the deal---marketing rights?. have they entered into any other deals for other parts of the world?

To: David Cathcart who wrote (684)	2/18/1998 1:33:00 AM
From: Vector1	Read Replies (2) \| Respond to of 1826

David, Yes a European deal would be great but the real driver of the stock will be Salagen sales. Interestingly the Company's sound financial footing makes it more difficult for them to get coverage. With almost 15m in cash and negligible burn they have no need to do a secondary offering. Analysts at major IBanks rarely pick up coverage of small cap stocks if there is not a strong likelihood of a significant fee generating event. MOGN's volume is not sufficient to peak interest. However if we start seeing sequential quarterly 30% sales increase then the company will become very difficult to ignore. Currently the company is significanly undervalued. With FDA approval in the bag and an average cost just under $5 a share I will sleep very well. V1